Indication
Mild to moderate Alzheimer's type dementia
Mild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults. Read more about Mild to moderate Alzheimer's type dementia
87 drugs 63 manufacturers
Drugs that treat it
Common Mild to moderate Alzheimer's type dementia therapies.
GALANTAMINE HBR
DONEPEZIL HCL
EXELON (rivastigmine)
GALANTAMINE HBR
DONEPEZIL HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults.
Pathophysiologically, it is characterized by the accumulation of extracellular amyloid-beta plaques, intracellular hyperphosphorylated tau neurofibrillary tangles, synaptic dysfunction, and widespread neuronal loss.
Clinically, this phase features noticeable short-term memory deficits, executive dysfunction, language impairment, and disorientation that progressively erode autonomy.
While patients initially struggle with complex instrumental activities of daily living—such as managing finances or medications—the moderate stage brings worsening confusion, behavioral changes, and an emerging need for assistance with basic personal self-care.
- fda.gov
Mild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults Pathophysiologically, it is characterized by the accumulation of extracellular amyloid-beta plaques, intracellular hyperphosphorylated tau neurofibrillary tangles, synaptic dysfunction, and widespread neuronal loss
- nih.gov
Mild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults
- nih.gov
Pathophysiologically, it is characterized by the accumulation of extracellular amyloid-beta plaques, intracellular hyperphosphorylated tau neurofibrillary tangles, synaptic dysfunction, and widespread neuronal loss
- fda.gov
Clinically, this phase features noticeable short-term memory deficits, executive dysfunction, language impairment, and disorientation that progressively erode autonomy
- nih.gov
Clinically, this phase features noticeable short-term memory deficits, executive dysfunction, language impairment, and disorientation that progressively erode autonomy While patients initially struggle with complex instrumental activities of daily living—such as managing finances or medications—the moderate stage brings worsening confusion, behavioral changes, and an emerging need for assistance with basic personal self-care
- nih.gov
While patients initially struggle with complex instrumental activities of daily living—such as managing finances or medications—the moderate stage brings worsening confusion, behavioral changes, and an emerging need for assistance with basic personal self-care
Personalize your experience
Follow Mild to moderate Alzheimer's type dementia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.